ArticleDrugs - real world outcomes2026
Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study.
Xiao-Yue Jiang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.